-

World Economic Forum Recognizes Agilent Facility in Singapore as a Leader in Advanced Manufacturing

The manufacturing site joins an exclusive list of facilities recognized for leveraging digital technology to increase performance while improving sustainability

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the World Economic Forum’s Global Lighthouse Network has named Agilent’s facility in Singapore a Fourth Industrial Revolution (4IR) leader for effectively deploying innovative technologies at scale in the manufacture of scientific instruments.

“Because of the incredible work of our team in Singapore, Agilent is among the leading manufacturers in our sector,” said Mike McMullen, president and CEO of Agilent. “We’re doing this for our customers, but also to provide a rewarding experience for our employees and to protect the environment.”

The Lighthouse is an initiative of the World Economic Forum in partnership with McKinsey & Company to showcase models of smart manufacturing enabled by 4IR technologies such as artificial intelligence and machine learning, robotics, data analytics, and the industrial internet of things.

By embracing 4IR technologies, Agilent’s Singapore facility has optimized productivity by 60% and increased output by 80%, all while advancing environmental sustainability through increased efficiency and greater reliance on renewable energy.

“We’re proud to receive this prestigious recognition, and we hope that others will be inspired to achieve their own technological breakthroughs on their 4IR journeys,” said Chow Woai Sheng, Agilent vice president of global instrument manufacturing and Singapore general manager. “This work also supports the government of Singapore’s Smart Nation Plan to spur economic growth through investment in digital technology.”

Agilent is deploying advanced digital technologies throughout its 28 manufacturing, operations and logistical sites across the world. These initiatives also contribute to Agilent’s goal of achieving net-zero greenhouse gas emissions by 2050.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Media Relations, South Asia Pacific
Grace Thong
Agilent Technologies
+65 9688 2152
grace.thong@agilent.com

Global media relations
Sarah Litton
Agilent Technologies
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Relations, South Asia Pacific
Grace Thong
Agilent Technologies
+65 9688 2152
grace.thong@agilent.com

Global media relations
Sarah Litton
Agilent Technologies
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...

Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. Second-quarter GAAP net income was $339 million, or $1.20 per share. This compares with $215 million, or $0.75 per share, in the second quarter of 2025. Non-GAAP net income(3) was $423 million, or $1.49 per share, during the quarter, compar...
Back to Newsroom